InterMune Inc. Reports Operating Results (10-Q)

Author's Avatar
Apr 30, 2010
InterMune Inc. (ITMN, Financial) filed Quarterly Report for the period ended 2010-03-31.

Intermune Inc. has a market cap of $2.47 billion; its shares were traded at around $45.02 with and P/S ratio of 50.7. Intermune Inc. had an annual average earning growth of 2.1% over the past 10 years.ITMN is in the portfolios of Stanley Druckenmiller of Duquesne Capital Management, LLC.

Highlight of Business Operations:

Data from the 12-week regimens of the Phase 2b study of un-boosted danoprevir plus SOC were reported on April 14, 2010. Similar virologic response was observed in all danoprevir treatment groups throughout the 12 weeks and after 12 weeks of treatment. At a danoprevir dose of 600 mg twice daily, 86% of patients had levels of HCV RNA below the limit of detection (